NCT05448755Phase 2Completed

A Study of ELX-02 in Patients With Alport Syndrome

Study sponsor: Eloxx Pharmaceuticals, Inc. · ELOX

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2023-09-11Actual
Enrollment · participants3Actual
Source updated2026-02-24Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 6 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: The incidence and characteristics of adverse events. After: Measure: Number of Participants With Adverse Events Associated With Administration of 0.75 mg/kg of ELX-02 Once Daily.

Participant count type changed

Before: Estimated. After: Actual.

Enrollment · participant count changed

Before: 8 participants (planned). After: 3 participants (actual).

Completion date type changed

Before: Estimated. After: Actual.

Primary completion date changed

Before: 30 May 2023. After: 11 Sep 2023.

Recruitment status changed

Before: Recruiting. After: Completed.

Check registry source